Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07678931

Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis

Conditions: Seasonal Allergic Rhinitis (SAR)

Sex: All

Ages: 12 Years – 18 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 136

Sponsor: Chengdu Kangnuoxing Biopharma,Inc.

Location: Beijing Children's Hospital, Capital Medical University Beijing Beijing Municipality

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the quality of life, Pharmakokinetics(PK), Pharmacodynamics (PD) characteristics, and immunogenicity of subjects.

Eligibility Criteria

Inclusion Criteria: * Age range: ≥12 years to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07678931). StuddyBuddy aggregates publicly available trial information.